{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:06Z","timestamp":1791181446379,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In addition to dysregulated JAK\/STAT signaling, activation of the AKT\/mTOR pathway occurs in myelofibrosis, a myeloproliferative neoplasm with no approved therapies. We conducted a phase 1\/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera\/postessential thrombocythemia myelofibrosis subjects. Responses were evaluated in 30 patients of phase 2. No dose-limiting toxicity was observed in phase 1 up to 10 mg\/d. When this dose was used in phase 2, grade \u2265 3 toxicities were infrequent; the commonest toxicity was grade 1-2 stomatitis. Rapid and sustained splenomegaly reduction of &gt; 50% and &gt; 30% occurred in 20% and 44% of subjects, respectively. A total of 69% and 80% experienced complete resolution of systemic symptoms and pruritus. Response in leukocytosis, anemia, and thrombocytosis occurred in 15%-25%. Clinical responses were not associated with reduced JAK2V617F burden, circulating CD34+ cells, or cytokine levels, whereas CCDN1 mRNA and phospho-p70S6K level, known targets of mTOR, and WT1 mRNA were identified as possible biomarkers associated with response. Response rate was 60% when European Network for Myelofibrosis criteria were used (8 major, 7 moderate, 3 minor responses) or 23% when IWG-MRT criteria (1 partial response, 6 clinical improvements) were used. These results provide proof-of-concept that targeting mTOR pathway in myelofibrosis may be clinically relevant.<\/jats:p>","DOI":"10.1182\/blood-2011-01-330563","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T11:30:02Z","timestamp":1309779002000},"page":"2069-2076","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":134,"title":["Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis"],"prefix":"10.1182","volume":"118","author":[{"given":"Paola","family":"Guglielmelli","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marchioli","sequence":"additional","affiliation":[{"name":"Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Masciulli","sequence":"additional","affiliation":[{"name":"Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tozzi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Biamonte","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bartalucci","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gattoni","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Lupo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pancrazzi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Susini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pieri","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Malevolti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Usala","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Ospedale A. Businco, Cagliari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaldo","family":"Occhini","sequence":"additional","affiliation":[{"name":"UOC di Ematologia, Ospedale San Donato, Arezzo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Grossi","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale di Prato, Prato, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Caglio","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA, Origgio, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Paratore","sequence":"additional","affiliation":[{"name":"Novartis Farma SpA, Origgio, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111807335933400_B1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms.","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"2019111807335933400_B2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia.","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111807335933400_B3","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"2019111807335933400_B4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111807335933400_B5","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis.","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111807335933400_B6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"6","key":"2019111807335933400_B7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2019111807335933400_B8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111807335933400_B9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2019111807335933400_B10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","article-title":"Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.","volume":"13","author":"Geron","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111807335933400_B11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.","volume":"32","author":"Ugo","year":"2004","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111807335933400_B12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"issue":"17","key":"2019111807335933400_B13","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"2019111807335933400_B14","doi-asserted-by":"crossref","first-page":"2914A","DOI":"10.1182\/blood.V114.22.2914.2914","article-title":"The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms.","volume":"114","author":"Vannucchi","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111807335933400_B15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111807335933400_B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer.","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"8","key":"2019111807335933400_B17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/13543784.2010.499121","article-title":"New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.","volume":"19","author":"Albert","year":"2010","journal-title":"Exp Opin Invest Drugs"},{"issue":"4","key":"2019111807335933400_B18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"2019111807335933400_B19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment.","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111807335933400_B20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"8","key":"2019111807335933400_B21","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111807335933400_B22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111807335933400_B23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111807335933400_B24","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111807335933400_B25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","article-title":"A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.","volume":"10","author":"Pancrazzi","year":"2008","journal-title":"J Mol Diagn"},{"issue":"1","key":"2019111807335933400_B26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","article-title":"Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).","volume":"25","author":"Guglielmelli","year":"2007","journal-title":"Stem Cells"},{"issue":"12","key":"2019111807335933400_B27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111807335933400_B28","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111807335933400_B29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111807335933400_B30","doi-asserted-by":"crossref","first-page":"460A","DOI":"10.1182\/blood.V116.21.460.460","article-title":"A phase I\/II study of CYT387, an oral JAK-1\/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms.","volume":"116","author":"Pardanani","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111807335933400_B31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMe1005856","article-title":"From palliation to targeted therapy in myelofibrosis.","volume":"363","author":"Vannucchi","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807335933400_B32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"27","key":"2019111807335933400_B33","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis.","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2069\/1347845\/zh803411002069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2069\/1347845\/zh803411002069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:37:13Z","timestamp":1712576233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/8\/2069\/29434\/Safety-and-efficacy-of-everolimus-a-mTOR-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-330563","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}